Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients (NCT03650894)
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The goal of this protocol is to evaluate the safety and efficacy of an alternative systemic combination approach that omits or delays the use of chemotherapy in metastatic disease, while improving efficacy and durability of response. The approach combines two potentially effective and previously studied strategies: androgen receptor blockade and immune checkpoint therapy.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Center — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Memorial Sloan Kettering Cancer Center — New York, New York
- Providence Oncology & Hematology Care Clinic - Eastside — Portland, Oregon
📞 Contact the Study Coordinator
Phone: (800) 525-2225
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasm Female
- RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy — St Louis, Missouri
- A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2) — Darlinghurst, New South Wales
- Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response — Iowa City, Iowa
- The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI — Washington D.C., District of Columbia
Explore by condition: All Breast Neoplasm Female clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.